Xeris Biopharma Holdings, Inc.XERSNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
14.41%
↓ 37% below average
Average (8y)
22.93%
Historical baseline
Range
High:101.60%
Low:-65.38%
Volatility
728.1%
High variability
| Period | Value |
|---|---|
| 2024 | 14.41% |
| 2023 | 6.56% |
| 2022 | -16.67% |
| 2021 | 20.26% |
| 2020 | -65.38% |
| 2019 | 48.66% |
| 2018 | 101.60% |
| 2017 | 96.97% |
| 2016 | 0.00% |